Sionna Therapeutics (SION) Net Cash Flow (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Net Cash Flow data on file, last reported at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 89.15% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at -$19.4 million (down 33882.46% YoY), and the FY2025 full-year result was $20.7 million, up 2919.1% from the prior year.
• Net Cash Flow retreated to $4.9 million in Q1 2026, from $7.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $44.9 million in Q1 2025 to a low of -$41.7 million in Q2 2025.
• A 3-year average of $2.8 million and a median of $4.9 million in 2026 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 273.76% in 2025 and tumbled 89.15% in 2026, its largest moves.
• Tracing SION's Net Cash Flow over 3 years: stood at $2.0 million in 2024, then jumped by 273.76% to $7.6 million in 2025, then tumbled by 36.06% to $4.9 million in 2026.
• Business Quant data shows SION's Net Cash Flow at $4.9 million in Q1 2026, $7.6 million in Q4 2025, and $9.8 million in Q3 2025.